Cramer's Morning Take: Eli Lilly 4/30/24

Jim and Jeff discuss Eli Lilly after the company beat on quarterly profit and hiked its full-year guidance on strong sales of Mounjaro and Zepbound. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer